Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida-Reference-Cited by-同舟云学术

Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida

Published:2018-03-05 Issue:6 Volume:34 Page:1099-1115
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Tanton Damon¹,Duh Mei Sheng²,Lafeuille Marie-Hélène³,Lefebvre Patrick³,Pilon Dominic³,Zhdanava Maryia³,Emond Bruno³,Inman Doreen⁴,Bailey Robert A.⁴

Affiliation:

1. Florida Hospital Research Institute, Orlando, FL, USA;

2. Analysis Group Inc., Boston, MA, USA;

3. Analysis Group, Inc., Montréal, QC, Canada;

4. Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Funder

Janssen Scientific Affairs

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1444591

Reference46 articles.

1. Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

2. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

3. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

4. Type 2 Diabetes-a Matter of ß-Cell Life and Death?

5. The importance of β-cell management in type 2 diabetes

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study;Journal of Clinical Medicine;2023-06-25

2. Canagliflozin: metabolic, cardiovascular and renal protection;Future Cardiology;2021-05

3. Cardiometabolic risk factor control in black and white people in the United States initiating sodium‐glucose co‐transporter‐2 inhibitors: A real‐world study;Diabetes, Obesity and Metabolism;2020-09-10

4. Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study;Journal of Clinical Medicine;2020-07-17